BioVaxys Technology Corp. is developing its patented DPX™ platform to address the challenges of lipid nanoparticles (LNPs) in mRNA vaccine delivery. Learn how DPX improves stability, immune responses, and manufacturing economics as the mRNA vaccine market projects $48 billion growth by 2030.